Pashtoon M. Kasi, MD, MBBS, MS, discusses how the triplet regimen of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab, will impact the treatment landscape for patients with metastatic colorectal cancer.
Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at the Mayo Clinic, discusses how the triplet regimen of the BRAF inhibitor encorafenib (Braftovi), the MEK inhibitor binimetinib (Mektovi), and the EGFR inhibitor cetuximab (Erbitux), will impact the treatment landscape for patients with metastatic colorectal cancer (mCRC).
Kasi believes this is another treatment option for this patient population. Historically, there has not been just 1 wonder drug that led to improvement in survival. Rather, the use of 1 drug or combination after another improves survival in this patient population.
This regimen will be moved to earlier lines of therapy for subsets of patients who only received 1 line of chemotherapy, Kasi says. Responses and durability have already been seen in this subset, so studies are now looking at moving this regimen to earlier lines.
Based on the findings from the BEACON CRC trial, this regimen was granteda breakthrough designation from the FDA in August 2018